Reports Q4 revenue $426,000 vs $173,000 last year. “We successfully executed against key strategic priorities in 2023, the most important of which was to lay the groundwork for our product pipeline and services portfolio to start generating significant revenues in 2024,” commented Dwight Gorham, IntelGenx’s CEO. “To that end, we expect that our commercial partner for RIZAFILM(R)1, Gensco Pharma, will be launching the product in the United States in Q2-2024, an anticipated inflection point for our business.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IGXT:
- IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results
- IntelGenx Set to Unveil 2023 Financial Results
- IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow
- IntelGenx Boosts Finances with Revised atai Agreement
- IntelGenx enters amended, restated loan agreement with atai Life Sciences